BIOMAT Database Logo BIOMAT Database Logo

[Clinical use of a Soviet polyvalent corpuscular pyocyanic vaccine for the prevention of Pseudomonas aeruginosa infection in thermal burn victims]. 1980

L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002056 Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like. Burn
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
[Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
January 1981, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
[Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine].
July 1985, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
[Effectiveness of a polyvalent corpuscular Pseudomonas aeruginosa vaccine, antibiotics and their combinations in experimental chronic Pseudomonas aeruginosa infection].
March 1985, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
[Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
October 1981, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
[Protective action of a corpuscular polyvalent Pseudomonas aeruginosa vaccine against representative enterobacteria].
April 1985, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
[Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia].
March 1986, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
[Use of a vaccine for prevention of Pseudomonas aeruginosa infection of burn wounds in mice].
June 1979, Polski przeglad chirurgiczny,
L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine.
January 1979, Archives roumaines de pathologie experimentales et de microbiologie,
L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
Study of the immunogenicity of the Pseudomonas aeruginosa polyvalent corpuscular vaccine in human volunteers.
January 1979, Archives roumaines de pathologie experimentales et de microbiologie,
L I Gerasimova, and A F Moroz, and S A Radkevich, and A I Sveshnikov, and E V Mizikin
[Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
May 1983, Antibiotiki,
Copied contents to your clipboard!